Evidence map›Paper›PMID 41095890›Full record

ArticleJournal of clinical medicine2025

Increased Rate of Anemia and Discontinuation in Older Patients with Myelofibrosis Treated with Ruxolitinib.

Alessandro Laganà, Emilia Scalzulli, Ida Carmosino, Maria Laura Bisegna, Claudia Ielo, Costanza Andriola, Maurizio Martelli, Massimo Breccia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alessandro LaganàHematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University, 00161 Rome, Italy.ORCID 0009-0005-9432-224X
Emilia ScalzulliHematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University, 00161 Rome, Italy.
Ida CarmosinoHematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University, 00161 Rome, Italy.
Maria Laura BisegnaHematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University, 00161 Rome, Italy.
Claudia IeloHematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University, 00161 Rome, Italy.
Costanza AndriolaHematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University, 00161 Rome, Italy.
Maurizio MartelliHematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University, 00161 Rome, Italy.
Massimo BrecciaHematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University, 00161 Rome, Italy.ORCID 0000-0003-1163-6162

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ageelderlyMyelofibrosis (MF)oldRuxolitinib (RUX)spleen response (SR)young

Identifiers

PMID41095890
PMCPMC12524875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.